Key result
Digital outreach increases 6-month SGLT2 inhibitor initiation by ~127% vs usual care.
Why the trial?
SGLT2 inhibitors improve heart failure outcomes yet remain underprescribed in routine care. EMAIL-HF tested whether a direct-to-patient digital outreach strategy can close this implementation gap and increase initiation of guideline-recommended therapy.
Does a digital outreach strategy improve SGLT2 inhibitor initiation in patients with heart failure?
Population
Patients with heart failure (sample size not reported in the record)
Comparison
Digital outreach strategy for SGLT2 inhibitor initiation vs usual care
Follow-up
6 months
Authors
No takes yet. Share an insight, caveat, or question.
Experts see EMAIL-HF as a successful implementation story that doubled SGLT2 inhibitor uptake, though clinical outcomes did not separate, leaving the field focused on closing the evidence-to-practice gap rather than expecting hard endpoint gains from digital outreach alone.
Clinicians frame EMAIL-HF as a proof of concept that digital strategies can meaningfully increase use of proven heart failure therapies. The reaction is uniformly positive about the prescribing signal but tempered by the absence of a clinical outcome benefit so far. The open question is whether higher SGLT2 inhibitor uptake through these pathways will eventually translate into fewer hospitalizations and deaths with longer follow-up or larger scale.
Commentators agree that the main takeaway is an implementation win: digital outreach can close the gap between guideline-recommended SGLT2 inhibitor therapy and real-world prescribing in heart failure, even if hard clinical endpoints did not improve in this timeframe.
2 takes classified by contention axis so far — the map appears as more land.
Whether the doubling of SGLT2 inhibitor initiation will translate into clinical outcome benefits with longer follow-up or in a trial powered for hard endpoints remains unanswered. It is also unclear how generalizable the digital strategy is across different health systems and patient populations.
Highlights that a digital strategy more than doubled SGLT2 inhibitor initiation in nearly 6,000 patients with heart failure. Frames the result as evidence that digital pathways can move proven therapies from guidelines into practice.
Edgardo Alania · Aug 30 Practice take Notes that the digital strategy doubled SGLT2i initiation with no early outcome benefit yet, arguing that "sometimes the breakthrough is getting proven therapy to the right patient." X post
Chacón-Lozsán F .'. · Aug 30 Context Frames the evidence-practice gap as an implementation problem rather than an efficacy problem, calling EMAIL-HF a very interesting pragmatic trial. X post
Digital outreach boosts SGLT2 inhibitor initiation in heart failure; extends implementation evidence for scalable GDMT interventions.
| Outcome | Digital | Usual care |
|---|---|---|
| SGLT2 inhibitor initiation at 6 months | 18.6% | 8.2% |
| p<0.001 favouring digital outreach | ||
| HF hospitalisation or death | 13.0% | 14.0% |
| Secondary outcome · p=0.276, not significant | ||
Statistical certainty
sample size, denominators and design details are not reported.
Design limitations
record is derived from the ESC press release with no simultaneous results paper, and clinical-outcome follow-up is limited to 6 months, too short to expect an initiation gain to translate into events.
Does a digital outreach strategy improve SGLT2 inhibitor initiation in patients with heart failure?
Absolute Event Rate: 18.6% vs 8.2%
p-value: p=<0.001
A digital outreach strategy significantly increased the initiation of guideline-directed SGLT2 inhibitors in patients with heart failure compared to usual care.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Mariam Elmegaard (2026) conducted an RCT in heart failure. digital outreach strategy vs. usual care was evaluated on SGLT2 inhibitor initiation (p=<0.001). A digital outreach strategy significantly increased SGLT2 inhibitor initiation at 6 months compared to usual care (18.6% vs 8.2%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: